BioNTech, Moves

BioNTech Moves to Full Control as CureVac Tender Clears Major Hurdles

Published on 12/11/2025 at 14:21 | Redaktion boerse-global.de

CureVac is undergoing a decisive transformation, shifting from an independent mRNA pioneer to a fully integrated unit within BioNTech. With the pivotal steps in motion, the takeover is effectively moving toward completion. For shareholders, the key question is what the present terms mean for their stake.

BioNTech Moves to Full Control as CureVac Tender Clears Major Hurdles Illustration mit AI erstellt übermittelt durch boerse-global.de
BioNTech Moves to Full Control as CureVac Tender Clears Major Hurdles Illustration mit AI erstellt übermittelt durch boerse-global.de

BioNTech Wins a Clear Majority

The takeover was effectively settled through the exchange tender. By the close of the first acceptance window, 184,071,410 CureVac shares had been tendered, representing about 81.74% of the issued and outstanding capital. This level meets the minimum acceptance threshold, clearing the path for the subsequent reorganization.

Under the deal, BioNTech will deliver American Depositary Shares (ADS) to those holders who accepted. The exchange ratio is Read more...

Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.

en | NL0015436031 | BIONTECH | boerse | 68417321 |